ABUS - アルブ―タス・バイオファ―マ (Arbutus Biopharma Corporation) アルブ―タス・バイオファ―マ

 ABUSのチャート


 ABUSの企業情報

symbol ABUS
会社名 Arbutus Biopharma Corp (アルブ―タス・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering developing and commercializing a cure for patients suffering from chronic hepatitis B infection a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development which has enabled several clinical trials and has been administered to hundreds of human subjects.   アルブ―タス・バイオファ―マはカナダのバイオ医薬品企業。主に先進リボ核酸(RNA)干渉(RNAi)治療薬の研究開発に取り組み、製薬企業パ―トナ―に脂質ナノ粒子送達技術を提供する。慢性B型肝炎感染の患者に特化し、B型肝炎ウイルス(HBV)による肝臓疾患に対する治療法の発見、開発、商業化に従事する。本社はブリティッシュコロンビア州。   Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
本社所在地 100-8900 Glenlyon Parkway Burnaby British Columbia V5J 5J8 CAN
代表者氏名
代表者役職名
電話番号 +1 604-419-3200
設立年月日 38626
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 130人
url www.arbutusbio.com
nasdaq_url https://www.nasdaq.com/symbol/abus
adr_tso
EBITDA EBITDA(百万ドル) -66.20400
終値(lastsale) 9.11
時価総額(marketcap) 504733154.78
時価総額 時価総額(百万ドル) 332.42580
売上高 売上高(百万ドル) 12.10600
企業価値(EV) 企業価値(EV)(百万ドル) 298.47880
当期純利益 当期純利益(百万ドル) -84.55700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arbutus Biopharma Corp revenues increased from $1.3M to $2.7M. Net loss applicable to common stockholders decreased 48% to $19.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Gain on investment increase from $0K to $24.9M (income).

 ABUSのテクニカル分析


 ABUSのニュース

   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   Why Arbutus (ABUS) Stock Might be a Great Pick  2020/05/15 15:04:00 Zacks Investment Research
Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Moving Average Crossover Alert: Arbutus Biopharma  2020/05/11 15:19:00 Zacks Investment Research
Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates  2020/03/05 13:55:02 Zacks Investment Research
Arbutus (ABUS) delivered earnings and revenue surprises of 2.70% and 10.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
   Arbutus Biopharma misses on revenue  2020/03/05 12:32:40 Seeking Alpha
Arbutus Biopharma (NASDAQ:ABUS): FY GAAP EPS of -$2.89. Revenue of $6.01M (+1.0% Y/Y) misses by $0.62M. Press Release
   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   Why Arbutus (ABUS) Stock Might be a Great Pick  2020/05/15 15:04:00 Zacks Investment Research
Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Moving Average Crossover Alert: Arbutus Biopharma  2020/05/11 15:19:00 Zacks Investment Research
Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates  2020/03/05 13:55:02 Zacks Investment Research
Arbutus (ABUS) delivered earnings and revenue surprises of 2.70% and 10.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
   Arbutus Biopharma misses on revenue  2020/03/05 12:32:40 Seeking Alpha
Arbutus Biopharma (NASDAQ:ABUS): FY GAAP EPS of -$2.89. Revenue of $6.01M (+1.0% Y/Y) misses by $0.62M. Press Release
   Moving Average Crossover Alert: Arbutus Biopharma  2020/05/11 15:19:00 Zacks Investment Research
Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates  2020/03/05 13:55:02 Zacks Investment Research
Arbutus (ABUS) delivered earnings and revenue surprises of 2.70% and 10.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
   Arbutus Biopharma misses on revenue  2020/03/05 12:32:40 Seeking Alpha
Arbutus Biopharma (NASDAQ:ABUS): FY GAAP EPS of -$2.89. Revenue of $6.01M (+1.0% Y/Y) misses by $0.62M. Press Release
   The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO  2019/10/10 11:31:01 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: …
   The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug  2019/10/09 11:58:26 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on Tuesday. Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 8.) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Albireo Pharma Inc (NASDAQ: ALBO ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BIOLASE Inc (NASDAQ: BIOL ) BioTelemetry Inc (NASDAQ: BEAT ) CELYAD SA/ADR (NASDAQ: CYAD ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Clovis Oncology Inc (NASDAQ: CLVS ) (Goldman reiterated a Sell rating on the stock and cut the price target from $13 to $3.) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Endologix, Inc.

 関連キーワード  (医薬品 米国株 アルブ―タス・バイオファ―マ ABUS Arbutus Biopharma Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)